Latest Healthcare News

EBOS Group Limited has reported a 9% drop in revenue and an 18.9% fall in net profit for the first half of fiscal 2025, yet it maintains its interim dividend at 57 NZ cents per share.

Enlitic has announced a strategic collaboration with GE HealthCare to deploy AI-driven technology that will transform the migration of medical imaging data, promising faster, more secure transitions and enhanced data quality for healthcare providers worldwide.

Ansell Limited has updated its FY25 interim dividend details, confirming a payment of USD 0.222 per share with an AUD equivalent of 0.3486, payable on March 6, 2025.

Cardiex Limited has confirmed to the ASX that it holds no undisclosed information explaining the recent spike in its share price, affirming full compliance with continuous disclosure rules.

Osteopore Limited has drawn down A$2 million from the first tranche of its redeemable convertible notes, using the proceeds to repay existing loans and support ongoing business activities.

ResMed Inc. has updated the foreign exchange rate impacting its upcoming dividend payment to Australian CDI holders, reflecting currency volatility and tax treaty benefits.

Ecofibre Limited has restructured its Australian loan facilities, extending repayment terms and adjusting interest rates to support a more sustainable financial footing.

Wellnex Life Limited has locked in A$9 million in conditional commitments to support its proposed dual listing on the London Stock Exchange’s AIM market, alongside launching a 1:1 entitlement offer for existing shareholders.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Imugene’s Phase 1b trial of azer-cel, an off-the-shelf CD19 CAR T therapy, reports a 57% complete response rate in heavily pretreated diffuse large B-cell lymphoma patients, signaling a promising new option in a challenging cancer landscape.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.